Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...
Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...
Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...
The stock's fall snapped a two-day winning streak.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show gains.
A Suffolk Superior Court judge dismissed a biomanufacturing company’s lawsuit that claimed disruption caused by a Kendall ...
Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.